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The success of cancer vaccines is dependent on the delivery of tumor-associated antigens (TAAs) within lymphoid tissue in
the context of costimulatory molecules and immune stimulatory cytokines. Dendritic cells (DCs) are commonly utilized to
elicit antitumor immune responses due to their attractive costimulatory molecule and cytokine expression proﬁle. However, the
eﬃcacy of DC-based vaccines is limited by the poor viability and lymph-node migration of exogenously generated DCs in vivo.
Alternatively, adoptively transferred T cells persist for long periods of time in vivo and readily migrate between the lymphoid
and vascular compartments. In addition, T cells may be genetically modiﬁed to express both TAA and DC-activating molecules,
suggesting that T cells may be ideal candidates to serve as cellular vehicles for antigen delivery to lymph node-resident DCs in vivo.
This paper discusses the concept of using T cells to induce tumor-speciﬁc immunity for vaccination against cancer.
1. Properties of an EffectiveCancer Vaccine
Therapeutic cancer vaccines aim to induce antitumor im-
mune responses through the generation of cytotoxic T cell
responses to tumor-associated antigens (TAAs). TAAs are
proteins that are either uniquely expressed (e.g., cancer
testes antigens, mutated proteins, and viral antigens) or
expressed to a higher degree (e.g., overexpressed proteins
and diﬀerentiation antigens) by tumor cells [1]. The success
of a cancer vaccine is contingent on (1) eﬃcient antigen
delivery to sites of T cell priming within lymphoid tissue
and (2) antigen presentation in the context of costimulatory
molecules and immunostimulatory cytokines.
To achieve these goals, a variety of cancer vaccination
strategies have been tested clinically, ranging from simple
peptide vaccines to more sophisticated approaches using
plasmid DNA, viruses, tumor cells, and dendritic cells (DCs)
[2]. To date, DC-based vaccine approaches have been most
e x t e n s i v e l yp u r s u e db e c a u s eD C sa r ec o n s i d e r e dt ob et h e
mostpotentprofessionalantigenpresentingcells(APCs)due
to their superior ability to take up, process, and present
antigens [3]. Immature DCs reside in peripheral tissues and
augment antigen presenting capacity upon activation via the
upregulation of MHC class I and II as well as the costim-
ulatory molecules CD80, CD86, and CD83. Concomitantly,
activated DCs upregulate CCR7 expression and migrate to
T cell zones within lymph nodes, where T cell priming
occurs [4]. DCs pulsed with tumor antigens have led to
protective immunity and tumor regression in mouse models
of cancer [5], and there are a multitude of completed and
ongoing vaccine trials in humans that have demonstrated T
cell mediated immune responses following DC vaccination.
2. Limitation of CurrentStrategies
Although much excitement has been generated recently
over the FDA approval of sipuleucel-T following prolonged
survival in prostate cancer patients [6, 7], the eﬃcacy
of DC-based vaccines remain limited in several regards.
First, DCs are a terminally diﬀerentiated cell type that
cannot be expanded ex vivo, resulting in limited numbers
of cells with which to vaccinate patients. Furthermore, upon
administration of DCs to patients, the vast majority of cells
are sequestered at the injection site and fail to migrate to
draining lymph nodes [8, 9] .D Cv i a b i l i t ya sw e l la sp e p t i d e -
MHC complex integrity is lost after 24–48 hours [10], and
sequestration allows ample time for DC dediﬀerentiation,
which may result in immune tolerance rather than activation2 Journal of Biomedicine and Biotechnology
[11]. Attempts to bypass cellular sequestration such as
intranodal DC injection are technically diﬃcult as evidenced
by an injection accuracy of only 50% despite ultrasound
guidance at the hands of an experienced radiologist [12].
The net eﬀect of these limitations is poor antigen deliv-
ery to lymphoid tissue and antigen presentation in the
absence of immune-stimulatory signals. These limitations
have most likely contributed to the low objective clinical
responses observed in DC-based vaccine trials. In the case
of melanoma, an immunogenic tumor where TAAs have
been clearly identiﬁed and inﬁltrating lymphocytes are often
observed, clinical response rates may be as high as 10%
[13]. However, the overall eﬃcacy of DC-based vaccines has
been disappointing when tumor types other than melanoma
are taken into account, producing clinical response rates
of only 4% [2, 14]. The limited success of DC vaccines
can to some extent be attributed to suboptimal vaccination
strategies performed in phase I clinical trials, such as the use
of immature DCs, lack of vaccine adjuvants, and targeting of
single MHC class I-restricted epitopes. Despite an increased
understanding of necessary vaccine components, the thera-
peutic eﬃcacy of DC vaccines is yet to improve signiﬁcantly.
Thus,whileDCvaccinationremainsanattractivestrategy,its
therapeutic eﬃcacy may be limited, and alternative vaccine
approaches should continue to be pursued.
3.TargetingDCIn Vivo
Much research has focused on various methods of DC matu-
ration ex vivo to maximize the expression of costimulatory
molecules, proinﬂammatory cytokines, and lymphotropic
chemokine receptors to optimize their function in vivo.
However, recent evidence has suggested that ex vivo-derived
DC vaccines may play a limited role in the priming of T
cells in vivo [15]. Antigen delivered by short-lived migratory
DCs can be processed by endogenous DCs within the lymph
node [16]. The immune eﬀects of exogenous DC vaccination
have been demonstrated to be contingent on the transfer
of antigen to endogenous DCs but not B cells, and antigen
transfer is not due to antigen diﬀusion, but rather DC-DC
molecular transfer [17]. Importantly, vaccination with apop-
totic or necrotic DCs abrogated vaccine eﬀects, indicating
thatviableDCsar eneededt omigrat et olymphoidtissueand
actively deliver antigen. The selective ablation of endogenous
lymphoid-resident DCs abrogated T cell responses following
DC vaccination, demonstrating the pivotal role this subset of
DCs plays in this phenomenon [18].
Murine lymphoid-resident DCs are characterized by the
expression of both CD11c and CD8α, and the human equiv-
alent to murine CD8α+ DCs has been recently identiﬁed
and is characterized by the expression of Clec9A (DNGR-
1), BDCA3, and XCR1 [19–22]. The CD8α+ DC subset has
been demonstrated to play an important role in the priming
of CD8+ T cells due to a unique capacity to cross-present
antigens via MHC class I [23–26] and produce high levels of
IL-12 following Toll-like receptor activation [27, 28]. CD8α+
DCs are strategically poised to engulf antigen entering the
l y m p hn o d ef r o mt h eb l o o da n dl y m p h a t i c sa sw e l la sf r o m
DCs migrating from the periphery into the lymph nodes.
Indeed, migratory DCs have been demonstrated to transfer
antigen to lymphoid-resident DCs and have led to CD8+
T cell priming following herpes simplex virus [29]a n d
inﬂuenza infection [30].
Appreciation for the important role CD8α+ DCs play
in CD8+T cell priming has spawned new targeted vaccine
strategies that aim to direct antigen speciﬁcally to DCs
in vivo, and thereby circumvent the various limitations of
exogenous DC vaccination [31]. One attractive approach is
to administer antigen conjugated to antibodies speciﬁc to
surface receptors shared by DCs and other cell types, such
as the mannose receptor or Fcγ receptors. The speciﬁcity
of DC-targeting can be narrowed by targeting more DC-
restricted receptors. Many of these receptors belong to the
C-type lectin receptor (CLR) family, such as DEC-205 and
DC-SIGN. Several CLRs have been identiﬁed to be expressed
uniquely on the surface of CD8α+ DCs, which allows
selective targeting of this particular DC subpopulation.
Both DEC-205 [32] and Clec9A (DNGR-1) [33, 34]h a v e
successfully served as targets for antibody-mediated antigen
delivery in vivo.
4. T Cells for Targeting DCs In Vivo
Although DC-targeted strategies using antibody-conjugated
antigens are attractive for large-scale clinical application,
this method of vaccination often requires the coadminis-
tration of immune adjuvants that lack clinical approval,
such as agonistic anti-CD40 antibodies. Cellular vehicles
like DCs are attractive options for vaccination because in
addition to the expression of antigen these cells express
the necessary costimulatory molecules and proinﬂammatory
cytokinesnecessaryforthegenerationofeﬀectivecytotoxic T
lymphocyte (CTL) responses. However, as stated previously,
exogenously generated DCs fail to eﬃciently deliver antigen
to lymphoid tissue. Therefore, a cell type that can eﬃciently
migrate to lymphoid tissue following infusion would be an
attractive vehicle for antigen delivery to lymphoid-resident
DC in vivo.
One potential cell type with lymphotropic properties is
the T cell. Subsets of T cells eﬃciently migrate from the
vasculature to the vicinity of CD8α+ DCs in the lymphatic
compartment [35]. Na¨ ıve or in vitro-expanded nonpolarized
T cells eﬃciently migrate to lymphoid tissues although T cell
polarization toward a type-1 or type-2 phenotype appears
to inhibit lymph node migration [35]. To deliver tumor
antigens, T cells can be surface-loaded with tumor peptides
orbegeneticallymodiﬁed toexpresswholeTAAs.Incontrast
to DCs, T cells can be expanded to large numbers ex vivo to
provideanabundanceofautologousantigendeliveryvehicles
to allow for the administration of large vaccinating cell doses
and increased frequency of vaccination.
T h ep o t e n t i a lu s eo fTc e l l sa sa n t i g e nd e l i v e r yv e h i c l e s
for vaccination was made apparent following the adoptive
transfer of herpes simplex virus thymidine kinase (HSV-TK)
gene-modiﬁed T cells to human subjects [36, 37]. Infusion
of T cells genetically modiﬁed with the foreign protein HSV-
TK induced robust CD4+ and CD8+ anti-HSV-TK T cell
responses which led to the destruction of transferred cellsJournal of Biomedicine and Biotechnology 3
[37]. In addition, HSV-TK gene modiﬁed T cells generated
memory T cells which led to a boosted T cell response upon
additional administrations of HSV-TK T cells. The diversity
and stability of the T cell response to HSV-TK generated by
gene-modiﬁed T cells suggested that antigen delivery by T
cells could function as a potential vaccination approach for
targeting viral or tumor antigens.
Tcellsgeneticallymodiﬁedtoexpressviralproteins,such
as inﬂuenza A matrix protein, have been demonstrated to
enhance the in vivo persistence of adoptively transferred
virus-speciﬁc T cells [38]. Although this ﬁnding suggests a
role for T cell-based vaccine approaches to boost adoptively
transferred T cells, much broader vaccine applications could
be attained following the demonstration that infusion of
antigen-loaded T cells could lead to the priming of T
cell responses to TAAs, which are most commonly weakly
immunogenic self-antigens. Russo et al. demonstrated that
T cells modiﬁed to express the melanoma TAA tyrosinase-
related protein 2 (TRP-2) could lead to the priming of TRP-
2-speciﬁc T cell responses following infusion [39]. Vaccina-
tion using TRP-2-modiﬁed T cells led to the establishment
of protective immunity and long-term memory responses in
B16F10 melanoma tumor-bearing mice. The authors were
able to demonstrate that CD8α+ DCs underwent maturation
following the phagocytosis of genetically modiﬁed T cells,
which could subsequently cross-present TRP-2 antigen and
prime TRP-2-speciﬁc T cell responses. Importantly, the
authors demonstrated that selective ablation of DCs prior
to vaccination with T cells modiﬁed to express ovalbumin
could not induce the expansion of adoptively transferred
CFSE-labeled OT-I T cells in vivo, validating that the
observed vaccine eﬀects were not mediated by direct antigen
presentation by T cells but rather antigen uptake and sub-
sequent presentation by endogenous DCs. These promising
results subsequently led to a clinical trial in which 10
melanoma patients were administered MAGE-A3 modiﬁed
lymphocytes [40]. MAGE-A3-speciﬁc T cell responses were
detectedin3/10patientsfollowingvaccination.Althoughthe
clinical outcomes following this vaccination strategy were
underwhelming, this study demonstrated the feasibility of
this approach for human application.
5.GeneticModiﬁcationstoEnhance
t h eI m m un eR e s po n s eF o ll o win gTC ell
Vaccination
Although T cells may eﬃciently deliver antigen to lymphoid
tissueinvivo,deliveryofantigenintheabsenceofconcurrent
DC maturation would likely lead to ineﬃcient T cell
priming or could even induce tolerance. The generation of
eﬀector T cell responses requires concurrent activation by
costimulatory molecules and proinﬂammatory cytokines at
the time of antigen presentation. Although T cells are not
themselves considered professional APCs, upon activation
T cells upregulate MHC class I and II molecules [41], the
costimulatory molecules CD80, CD83, and CD86 [42, 43]
as well as secrete proinﬂammatory cytokines such as IL-2,
IFN-γ,a n dT N F - α [44]. T cells can induce the proliferation
of resting T cells in mixed lymphocyte reactions [45]a n d
preferentially induce cytotoxic T cell responses [46]. T cells
arecapableofpresentingbothpulsedandtransducedviralor
tumor peptide antigens and can process full-length antigens
expressed from vectors [47, 48]. Taken together, these
observations suggest T cells may function independently of
DCs as APCs. However, the antigen presenting role T cells
play in vivo is likely insigniﬁcant compared to that of
professional APCs, due to the relatively lower expression of
costimulatory molecules and the complete lack of type-1
polarizing cytokines, such as IL-12. Hence, concurrent DC
activation at the time of vaccination is likely necessary to
induceeﬀectiveCTLresponsestoantigendeliveredbyTcells.
In addition to antigen expression, T cells may be further
modiﬁed to express molecules that induce DC maturation
(Figure 1). Maturation of DCs is most often mediated
through the activation of Toll-like receptors (TLRs). TLR-
ligands are well-conserved features of bacteria and viruses
known as pathogen-associated molecular patterns (PAMPs).
DCsexpressmanydiﬀerentTLRsthatcanrecognizeavariety
of PAMPs, such as lipopolysaccharide, double-stranded
RNA, and unmethylated CpG dinucleotides.
Flagellin is one TLR ligand of interest, because it is
one of the few TLR ligands that is a protein, allowing for
transgenicexpressionbyTcells.Flagellinisthemajorprotein
constituent of bacterial ﬂagellum and is recognized by TLR5.
TLR5 is expressed on the surface of DCs isolated from lymph
nodes [49]. Flagellin has been demonstrated to enhance the
priming of antigen-speciﬁc CD4+ T cells [50] which results
in a strong humoral response to produce protective antibod-
ies [51], and ﬂagellin fusion proteins have been shown to
augment the generation of antigen-speciﬁc CD8+ cytotoxic
Tcellresponses [51]. Flagellin,is a foreignprotein, thus anti-
ﬂagellin immune responses could potentially lead to the
elimination of ﬂagellin-expressing T cells and limit the eﬀec-
tiveness of vaccine boosting. However, preexisting immunity
to ﬂagellin does not appear to limit its eﬀectiveness as a
vaccine adjuvant [52, 53].
Variousendogenousproteins,suchasheatshockproteins
(HSPs), have been found to bind TLRs and lead to DC
maturation. HSPs play a central role in intracellular protein
folding and transport. They are an abundant intracellular
protein not expressed on the cell surface under normal
physiologic conditions. The presence of HSPs in the extracel-
lular compartment has been demonstrated to both facilitate
antigen uptake and presentation as well as act as a danger
signal to indicate cellular destruction due to bacterial or viral
infections or mechanical damage [54]. HSP-peptide com-
plexes can be internalized by professional APCs via receptor-
mediated endocytosis [55–57] leading to the induction of
not only helper CD4+ T cell responses via MHC class II
presentation,butalsoCD8+ CTLresponsesviaantigencross-
presentationonMHCclassImolecules.Furthermore,several
HSPs, such HSP60, HSP70, HSP90, gp96, and calreticulin,
have been shown to induce DC maturation via recognition
by TLR2 and TLR4 [58]. Surface expression of HSP70
and gp96 by tumor cells has been found to induce DC
maturation and lead to antitumor immune responses in vivo
[59, 60], and transgenic expression of gp96 in mice leads to


















Tc e l l
Tc e l l
Figure 1: Targeting dendritic cells (DCs) in vivo using T cells for cancer vaccination. Upon infusion, T cells eﬃciently home to lymphoid
tissue where they encounter lymph node-resident DCs. T cells may be genetically modiﬁed to express tumor-associated antigens as well as
molecules that can induce DC activation, such as CD40L, heat shock proteins (HSPs), and ﬂagellin. Interacting DCs engulf and present
antigen delivered by T cells on MHC class I and II molecules. T cell-mediated DC maturation results in the upregulation of costimulatory
molecules, such as CD80 and CD86, which are necessary for the generation of potent helper CD4+ and eﬀector CD8+ T cell responses.
expression could augment responses to TAAs delivered by T
cells.
TLR-independentDCmaturationcanbeachievedviathe
CD40 receptor. CD40 is a cell-surface receptor belonging to
the tumor necrosis factor-receptor family and is expressed by
a variety of cell types including B cells, monocytes, and DCs
as well as endothelial and epithelial cells [62]. The natural
ligand for CD40, CD154 (CD40L), is transiently expressed
by CD4+ T cells and serves as a positive feedback signal for
DCactivationfollowingTcellactivation.CD40cross-linking
induces DCs to upregulate MHC class II and costimulatory
molecule expression [63] as well as produce high levels
of proinﬂammatory cytokines [64]. CD40 signaling results
in CD8+ T cell priming independent of helper CD4+
T cells [65], and antibodies to CD40 can evoke strong
antitumor CD8+ T cell responses in vivo [66–68]. CD154
expression on the surface of activated CD4+ T cells is tightly
regulated, being expressed only transiently for <24 hours
[69]. Therefore, stable CD154 expression may be attained by
transgenic modiﬁcation of T lymphocytes. Using retroviral-
mediated gene modiﬁcation, Higham et al. modiﬁed tumor-
speciﬁc CD8+ T cells to express CD154 [70]. Despite stable
gene integration, transgenic CD154 expression remained
tightly regulated with decreasing expression 72 hours after
transduction. The authors were able to increase transgenic
CD154 expression by deletion of the intracellular domain
of CD154 and reactivation of T cells. CD154-expressing T
cells were subsequently demonstrated to mature DCs in vitro
as well as activate tolerogenic DCs within tumor draining
lymph nodes in vivo. Such an approach could be envisioned
to facilitate DC activation for the purpose of enhancing
immune responses to antigens delivered by T cells.
6. Summary
For cancer vaccines, delivery of antigen in the context
of immune stimulatory signals that activate lymph-node
resident DCs is a critical step in generating a robust anti-
tumor immune response. Because of their natural lymph-
node tropism and that they can be easily expanded ex
vivo and genetically modiﬁed to alter biologic function,
T cells represent a novel and ﬂexible platform for cancer
vaccinedesign.Inadditiontotransgenicexpressionoftumor
antigens and DC activating molecules, T cells may be further
modiﬁed to secrete cytokines (e.g., IL-2, IL-7, IL-12, IL-15,
and IL-21), improve tissue-speciﬁc migration via expression
of chemokine receptors (e.g., CCR7, CXCR4, and CCR2),
andexpressmoleculesthatsuppressimmuneregulatorycells,
including CD4+CD25+FoxP3+ regulatory T cells. In contrast
to more conventional DC vaccine strategies, we propose that
using T cells to deliver tumor antigens into lymphoid organs,
while providing essential immune activating signals required
for the induction of antitumor immune responses, may
ultimately improve the eﬃcacyof cell-basedcancervaccines.Journal of Biomedicine and Biotechnology 5
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